

Consensus Recommendations for the Assessment and Treatment of Rheumatoid Arthritis

The treatment of rheumatoid arthritis (RA) has changed dramatically during the last decade. The increasing use of methotrexate (MTX)¹⁻³, combination therapies⁴⁻⁶, and anti-tumor necrosis factor (TNF) agents⁷⁻¹² has made obsolete the treatment algorithms that have been in effect since the end of World War II, more than 50 years ago. With new agents have come higher costs¹³⁻¹⁷. Insurers and other payers have been uncertain how to approach RA treatment, but often have fallen back on the older algorithms such as the RA treatment pyramid¹⁸⁻²¹, and many clinicians still rely on these algorithms.

In the late autumn of 1999 we brought together a panel of rheumatology experts that included those with substantial experience and publications in clinical trials of RA treatments, assessment tool development, longitudinal assessment and outcome, and clinical practice. The group was charged with describing and evaluating the treatments, outcomes, assessments, and practices of the last half century. In addition, based on this evidence, they were asked to develop a consensus report for treatment of RA at the start of the 21st century. The committee was divided into subgroups, each of which worked on and produced research manuscripts concerning different aspects of the RA treatment question. These manuscripts are published separately as a part of this consensus symposium. In February 2000, the group met in Chicago for two days of discussion. The document below reflects the general consensus among these RA experts. Although this project was supported by Centocor, the company did not attend nor participate in the committee's deliberation. This work is entirely our own.

ASSESSMENT

The consequences of rheumatoid arthritis. RA is a chronic inflammatory disease that primarily effects large and small joints, but can also cause profound systemic alterations. The average duration of life following the onset of RA is about 27 years²². RA rarely remits²³, and then only briefly, and untreated maintains its severity over the lifetime of the patient²⁴. Almost all patients suffer daily pain²⁴⁻²⁶, and almost all

patients have functional loss^{24,27-37}. Although the severity of pain and functional loss spans a wide spectrum, from catastrophic and incapacitating illness to minor pain and limitation, almost all patients have some degree of limitation and discomfort from their illness. In addition, generally irreversible outcomes such as work disability^{30,38-46}, joint destruction and consequent surgery⁴⁷, and premature mortality are associated with the disease. Fully a quarter of RA patients may be expected to have a major joint replacement during their lifetime⁴⁷. Among those who are working at the onset of RA, between 35 and 50% will be work disabled after 10 years, and 50 to 75% will be disabled after 20 years^{38,39,44}. Mortality is doubled among patients with RA²², and radiographic damage progresses inexorably⁴⁸⁻⁵².

A misunderstanding of RA has come about from colloquial clinical language. In the clinical evaluation of RA, physicians may write "doing well," but most often such statements reflect a comparative assessment with RA patients whose activity is much more severe, or a sense that the patient is, in fact, coping well with the illness. "Limited disease," another term that is used in describing a patient, similarly does not mean being pain-free or having normal function.

In understanding RA and its treatment and outcome, certain key terms must be defined.

Disease activity. Disease activity refers to the systemic and local inflammatory manifestations of RA. The key clinical abnormality is synovitis. But synovitis as observed does not capture all the content of disease activity. Therefore a series of surrogate markers are used to identify disease activity. In practice, these surrogates include counts of swollen joints, counts of tender joints, patient assessment of pain and global severity, assessment of functional disability, and assessments of acute phase reactants such as erythrocyte sedimentation rate (ESR) and C-reactive protein. The surrogates form the American College of Rheumatology (ACR) Core Set of assessment measures as well as measures suggested by European and international groups⁵³⁻⁵⁷. Although they are useful in clinical care as well as randomized clinic trials (RCT)⁵⁸,

not all the measures are ordinarily collected in clinical practice⁵⁹. Detailed assessment methods for RA activity are described in a separate manuscript of this conference³⁷ and may be found elsewhere^{56,60-68}. Certain other aspects of RA illness may also be representative of disease activity, such as vasculitis, but are usually not part of the routine evaluation of the illness.

Disease activity occurs over a spectrum of severity. As described elsewhere in these proceedings, disease activity can be quantified by the Disease Activity Score (DAS) of van der Heijde^{67,68} or through the use of percentile values^{29,37}. Using the latter method, the status of RA patients can be determined in comparison with others with RA.

Disease severity. Disease severity (severe disease) is identified by (1) persistent high levels of disease activity; (2) substantial structural damage, functional loss, work disability, radiographic abnormality, and joint replacement; and (3) a rapidly accelerating illness that is expected to produce future substantial structural damage and other adverse outcomes.

The relationship between disease activity and the outcomes of RA. Disease activity is responsible for current symptoms. Disease activity acting over time leads to structural damage, functional loss, work disability, radiographic abnormality, joint replacement, premature mortality, and increased costs^{63,69-78}. The more severe the level of disease activity, the greater the risk of the longterm adverse outcomes and the shorter the duration to the outcomes^{22,38,44,47,52,79}.

Certain outcomes, such as work disability, can come about very quickly in the face of severe RA. Therefore very active disease can be considered as almost a medical emergency. But mild disease is not benign either, and leads to important damage and limitations even though it takes longer to get to those endpoints. It is a fundamental mistake to confuse tolerability and milder activity with good longterm outcome, for milder activity will also lead to functional loss and important life limitations.

TREATMENT

The goals of treatment. Given the role of disease activity in producing current symptoms and future damage and other adverse outcomes, the fundamental goal of treatment is to eliminate synovitis and disease activity; and where that is not possible the goal is to control synovitis and disease activity to the fullest extent possible.

Although these goals may seem commonplace, they represent a fundamental change in the approach to RA. ACR improvement criteria, which stress 20 or 50% improvement, may be required for RCT^{53,55}, but are not acceptable outcomes of RA treatment. The goal, from both the patient's perspective and the physician's, is to eliminate disease activity. Treatment failure, therefore, follows a simple definition: Treatment failure exists when disease activity is not controlled.

Beginning in the last decade of the 20th century a profound change came about in how experts viewed RA treatment. At

the same time it slowly became apparent that the outcomes of RA were changing for the better⁸⁰⁻⁸⁸. A number of factors brought about these changes. MTX achieving full acceptance in the 1990s was perhaps most responsible⁸⁹⁻⁹³. But other factors were also important, including earlier initiation of disease modifying antirheumatic therapy (DMARD)⁹⁴⁻¹⁰⁰ and combination therapy^{4,5,94,101-106}. As the century ended anti-TNF therapy was introduced¹⁰⁷⁻¹⁰⁹, and data from RCT indicated benefit beyond what might be expected from MTX treatment alone. In the wings stand other soon to be introduced "biotech" compounds.

With this change in therapy came a more general realization that it was possible to alter the outcome of RA for the better by appropriate use of treatment. But for almost the entirety of the 20th century prior to MTX, the outcome of RA was poor, and it was even difficult to detect treatment effect. Much of the century was concerned with identification and prevention of adverse effects of treatments, for if you could not really make patients better, at least, as the thought went, you would not make them worse. Many patients spoke of gold therapy as "the last resort," and in a sense it was. High rates of adverse reactions and discontinuations plagued gold therapy and other therapies such as sulfasalazine, penicillamine, azathioprine, and cyclosporin. A skillful and lucky physician might pilot the patient through these hazards, but it was never easy. But this outlook of limited benefit and adverse reactions has changed, and with it the principles of treatment have also changed.

Two other changes have occurred that have been important. First, measurement of RA disease activity and outcome has improved substantially, and it is now within the ability of practicing physicians to assess accurately the status, activity, and outcome of his or her patients^{59,110}. The second important change is that brought about by cost constraints^{111,112}. Because anti-TNF agents are expensive, controls have been placed on their use (by managed care in the US) even though they appear to be among the most effective treatments available. A second cost control involves the limited access to rheumatology experts that sometimes occurs, although rheumatologists are the persons most knowledgeable in the evaluation and prescription of RA therapy.

The pyramidal approach to RA treatment. The pyramidal approach to RA treatment recommended a "basic program" of nonsteroidal antiinflammatory drugs (NSAID), rest, heat, education, and physical therapy to which might be added, if necessary, DMARD therapy. Elsewhere in this symposium, Moreland, Russell, and Paulus review the various non-DMARD therapies that have been used in RA over the last half century. Examined over the course of decades, there is no scientific evidence to indicate that these recommendation therapies were in any way effective in substantially reducing symptoms or altering the course of RA. To the contrary, the recommendations have resulted in the delay in the use of DMARD, and to that extent have been harmful to patients

with RA. The basic program for RA treatment should be DMARD and/or biologic therapy.

The use of NSAID and/or analgesics. Not all patients benefit from or require NSAID and/or analgesic therapy, and there is no evidence that these treatments alter the course of RA^{113,114}. In addition, NSAID may cause adverse effects^{113,115}. Therefore the use of these agents should be considered optional. Many patients may achieve important reduction in symptoms from NSAID and/or analgesics. Therefore their use should be determined on a case by case basis. In many instances occasional use of NSAID will suffice. Whether regular, full dose NSAID use is helpful, compared to intermittent, reduced doses should be determined by trial in the individual patient.

Analgesics do not help in the control of RA disease activity, but can be helpful adjuncts for pain control. Both opioid and non-opioid analgesics can be useful. As with NSAID, analgesics should not be used as substitute for DMARD/biologic therapy when control of disease activity is required.

The Selection and Use of DMARD and/or Biologic (D/B) Agents

Who should be treated with D/B therapy? DMARD and/or biologics improve the signs, symptoms, and outcomes of RA. With rare exceptions, all RA patients should receive DMARD therapy. Since the goal of therapy is to control disease activity, this control should be sought through D/B therapy regardless of age except when concomitant or comorbid illness limits therapy. D/B therapy is tolerated equally in all age groups^{116,117}.

When to treat with D/B therapy. Treatment with D/B therapy should be begun as soon as possible after RA is diagnosed. Early treatment with D/B therapy is beneficial since effective therapy will retard outcomes such as work disability and may prevent or delay functional loss^{82,96,98,99,103,118-125}. Additionally, some data suggest that early treatment may alter the disease course by acting within "a window of opportunity." This latter point has not been extensively studied, but the benefits of treatment compared to delayed treatment are quite clear.

DMARD treatment is helpful in disease of long duration, too. The duration of disease should not be an indication for not using D/B therapy. The indication for treatment is the presence of disease activity, not the duration of disease.

The choice of a specific DMARD. Not all DMARD are equivalent or useful^{1,126}. Auranofin rarely works and cyclophosphamide is too toxic¹²⁷⁻¹²⁹. These DMARD should almost never be used in RA treatment. Longitudinal observational studies (LOS) and rheumatologist-preference studies indicate that MTX is the most effective RA treatment by far¹²⁶. There is little LOS data on leflunomide, etanercept, or infliximab, but RCT indicate that leflunomide and MTX are equivalent in efficacy¹³⁰ and that etanercept and infliximab (often in combination with MTX) are superior to MTX alone^{108,109,131-133}.

The most effective DMARD should be used first in the treatment of RA. For most patients this means MTX or leflunomide. There is little reason to recommend less effective DMARD as the drug of first choice except in some patients with very limited disease activity.

In the choice of RA therapy, however, the patient's preference is most important. Patients should be educated about the benefits and risks of treatment, but also about the risk of no treatment^{36,134}, something not usually considered by patients. Patients may wish to alter these treatment recommendations based on reasons of cost, convenience, or risk aversion, and these wishes should be respected. Additionally, psychological and social factors must be considered in D/B prescription.

Because many patients will respond adequately to MTX or leflunomide therapy, we do not recommend the use of etanercept or infliximab as first therapies, since only limited data exist on their effectiveness in these situations. However, recent reports regarding etanercept in recent onset RA suggest that anti-TNF agents may play a future role as first line treatments of RA. In the case of patients with very active disease, the use of anti-TNF agents together with MTX or leflunomide may be indicated together as first line treatment. There is no simple rule as to the order of treatments, and the use of D/B drugs in combination is clinically appropriate in the case of severe disease or where disease activity is not adequately controlled.

DMARD dosage. A full trial of a DMARD requires adequate dosage. Unless limited by toxicity, MTX dosage should be increased to 20 mg per week or greater unless an adequate response is achieved at a lower dosage. Full doses of sulfasalazine are 3 g per day. Anti-TNF agents are prescribed on fixed schedules. There are no data yet available to recommend "maximum" doses, although it is possible such information will appear in the future.

D/B treatment failure. As indicated above, treatment failure means the inability to control or eliminate disease activity after an adequate trial of the D/B. In general, an adequate trial is 5 months for injectable gold, 6 months for penicillamine, 4 months for hydroxychloroquine, and 3 months for all other DMARD and biologics. In some instances a full response may take longer than the times listed above and it may be appropriate to wait longer if in the view of the clinician an adequate response may be achieved by additional treatment time.

If a patient fails MTX and leflunomide, it is unlikely that he will have an adequate response to DMARD such as hydroxychloroquine, sulfasalazine, injectable gold, or azathioprine. In such situations treatment with combination therapy such as with the 3 drug combination of MTX, sulfasalazine, and hydroxychloroquine, or with etanercept or infliximab may be indicated without successive trials of gold, sulfasalazine, penicillamine, or azathioprine. This is particularly true when disease activity is high. When a patient is ill and disease activity is uncontrolled, that patient deserves the best available treatment, not the worst.

Corticosteroids. The role of corticosteroids in the treatment of RA remains controversial¹³⁵⁻¹³⁸, primarily because of concerns regarding the possibility of unacceptable levels of toxicity and longterm limited benefit. Although there seems to be strong evidence that steroids can improve some outcomes¹³⁹, rheumatologists remain divided over their use. When used, steroids should accompany D/B therapy and not be a substitute for such therapy. The use of NSAID and prednisone alone is not ordinarily appropriate treatment for RA.

Treatment algorithms. The committee's recommendations reflect general standards for the treatment of RA. But each patient's care must be individualized. For some patients the recommendations here will be too aggressive and for others they will be too limited.

The evaluation of RA status and activity. To understand whether therapy is needed or works, disease activity must be documented. While it is appropriate to do this for patient care reasons alone, 3rd party payers increasingly require documentation to support use of modern therapies. Disease activity can be documented using the items of the ACR core set⁵⁵, including patient visual analog pain and global severity scales, ESR or CRP, a count of swollen and tender joints, and a functional scale such as the Health Assessment Questionnaire (HAQ) or the modified (M) HAQ. But performing and recording detailed tender and swollen joint counts at each clinic visit can be burdensome to the point of interfering with patient care, and may not be required for good patient care. Therefore while the most comprehensive evaluation can be performed using all of the ACR core set items, a reduced set of measures can perform almost as well^{37,59}.

The pain, global severity, and HAQ/MHAQ assessments can be obtained directly from the patient by self-report questionnaire^{37,59}. When used with acute phase reactants, these measures can provide necessary documentation. Detailed swollen and tender joints add still more information, but can be replaced with either shortened swollen joint counts or shortened tender joint counts, or possibly both, as described elsewhere in the symposium³⁷. Other documentation, such as grip strength or morning stiffness, can also be helpful. Regardless of the documentation employed, it is important that they be recorded serially and not on a hit or miss basis^{37,59}.

RECOMMENDATIONS

In the consensus recommendations below we suggest a general set of guidelines by which RA can be treated more effectively. But guidelines are just guidelines. They are not absolute recommendations or inflexible rules, nor are they meant to be. There will be times when the correct decision will not be the one we have recommended here. Individual patient differences, patient preferences, and the presence of psychosocial factors and comorbid conditions will often dictate the correct management course. The knowledgeable physician, who always knows more about his or her patient than a committee of experts, may appropriately treat more or

less aggressively than we have recommended. We hope that these guidelines will be used by physicians and insurance companies to appreciate the new paradigms in RA treatment, and to extend this change in approach to RA patients everywhere.

1. The fundamental goal of RA treatment is to eliminate synovitis and disease activity.
2. With few exceptions, all patients should be treated with a DMARD or a biologic agent. Exceptions are based on comorbid conditions, age, patient preference, or the presence of very limited disease activity.
3. When disease activity is present, the treatment recommendations apply regardless of duration of disease or patient's age.
4. The most effective DMARD should be used first.
5. In the US, the most commonly used DMARD is methotrexate. A treatment program that includes MTX or an equivalent drug is appropriate for 85% of RA patients at the initial clinical evaluations.
6. DMARD should be used at full doses unless full treatment effect is gained at lower dosage or limiting toxicity is reached. For MTX the full dose is at least 20 mg per week; for sulfasalazine it is 3 g per day.
7. Treatment should be begun promptly following rheumatology evaluation^{112,140-142}. The initial evaluation of RA usually takes one to two rheumatology visits. It is sometimes desirable to await the results of laboratory tests and/or the response to therapy given at the first visit before starting definitive RA treatment. But this delay should be conditioned on specific needs, and first visit definitive treatment may be appropriate.
8. A patient fails a DMARD/biologic if the disease activity is not adequately controlled.
9. In general, an adequate DMARD trial is 5 months for injectable gold, 6 months for penicillamine, 4 months for hydroxychloroquine, and 3 months for all other DMARD and biologics. In some instances a full response may take longer than the times listed above and it may be appropriate to wait longer if in the view of the clinician an adequate response may be achieved by additional treatment duration.
10. When adequate control is not achieved, the DMARD should be changed or another DMARD or biologic agent added.
11. There is a hierarchy of DMARD/biologics. Patients who do not respond adequately to MTX or leflunomide will only occasionally respond to another DMARD. In such patients the switch to or addition of a biologic may be indicated without further DMARD trials. Alternatively, triple drug combination with MTX, sulfasalazine, and hydroxychloroquine may be indicated, as may the addition of cyclosporine.
12. Most patients will not respond completely to DMARD/biologic therapy. In such patients the most effective treatment should be used, and continuous switching from one DMARD to the next is not generally good policy or likely to be effective.
13. Biologics may be appropriate at any time during the treat-

ment process depending upon disease and response. Anticytokine therapy should not be reserved for advanced disease or DMARD resistant disease, and appropriately should be used to treat rapidly advancing, aggressive disease.

14. Prognostic factors should be considered in the prescription of DMARD, including radiographic progression.

15. Weak (auranofin) and toxic (cytoxan) DMARD are seldom used and not advised.

16. Corticosteroids remain controversial because of concerns about toxicity, but many rheumatologists believe that low dose (10 mg or less) is effective and safe.

17. The use of NSAID and/or simple analgesics is not required, but is an adjuvant that is suitable for some patients. It is not correct to condition DMARD use on a trial of NSAID.

18. All treatments must consider the medical, social, psychological, and economic status of the patient. Patient preferences are important.

19. Toxicity of drugs should be considered in their prescription.

20. Treatment initiation and assessment of treatment success require rheumatologic assessment of disease activity. That process should be modeled on the ACR core criteria and includes assessments of pain, global severity, function, acute phase reactants, and joint counts, at a minimum.

FREDERICK WOLFE, MD.

National Data Bank for Rheumatic Diseases—Arthritis Research Center Foundation, Inc. and University of Kansas School of Medicine, Wichita, Kansas;

JACK J. CUSH,

Arthritis Center, Presbyterian Hospital of Dallas, Dallas, Texas;

JAMES R. O'DELL, MD.

Professor of Medicine, University of Nebraska School of Medicine, Omaha, Nebraska;

ARTHUR KAVANAUGH, MD.

Associate Professor of Medicine, University of California at San Diego, San Diego, California;

JOEL M. KREMER,

Professor of Medicine, Albany Medical College, Albany, New York;

NANCY E. LANE, MD.

Associate Professor of Medicine and Rheumatology, University of California at San Francisco, San Francisco, California;

LARRY W. MORELAND, MD.

Professor of Medicine, Director, UAB Pittman General Clinical Research Center, The University of Alabama at Birmingham, Birmingham, Alabama 35294;

HAROLD E. PAULUS, MD.

Professor of Medicine, University of California Los Angeles, Los Angeles, California 90095;

THEODORE PINCUS, MD.

Professor of Medicine, Vanderbilt University, Nashville, Tennessee, USA;

ANTHONY S. RUSSELL, MD.

University of Alberta, Edmonton, Alberta, Canada;

KENNETH R. WILSKIE, MD.

Virginia Mason Clinic, Seattle, Washington, USA.

REFERENCES

1. Wolfe F, Albert DA, Pincus T. A survey of United States rheumatologists concerning effectiveness of disease-modifying antirheumatic drugs and prednisone in the treatment of rheumatoid arthritis. *Arthritis Care Res* 1998;11:375-81.
2. Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: Followup after a mean of 13.3 years. *Arthritis Rheum* 1997;40:984-5.
3. Rau R, Schleusser B, Herborn G, Karger T. Longterm treatment of destructive rheumatoid arthritis with methotrexate. *J Rheumatol* 1997;24:1881-9.
4. Furst DE. The combination of methotrexate, sulfasalazine and hydroxychloroquine is highly effective in rheumatoid arthritis. *Clin Exp Rheumatol* 1999;17:39-40.
5. Odell JR. Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis. *Rheum Dis Clin N Am* 1998;24:465.
6. Rau R, Schleusser B, Herborn G, Karger T. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy. *J Rheumatol* 1998;25:1485-92.
7. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med* 1999;340:253-9.
8. Kavanaugh AF. Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. *Rheum Dis Clin N Am* 1998;24:593.
9. Moreland LW. Soluble tumor necrosis factor receptor (p75) fusion protein (Enbrel) as a therapy for rheumatoid arthritis. *Rheum Dis Clin N Am* 1998;24:579.
10. Wallis WJ, Furst DE, Strand V, Keystone E. Biologic agents and immunotherapy in rheumatoid arthritis: Progress and perspective. *Rheum Dis Clin N Am* 1998;24:537.
11. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. *N Engl J Med* 1997;337:141-7.
12. Moreland LW, Heck LW, Koopman WJ. Review: Biologic agents for treating rheumatoid arthritis — Concepts and progress. *Arthritis Rheum* 1997;40:397-409.
13. Clarke AE, Levinton C, Joseph L, et al. Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis. *J Rheumatol* 1999;26:1068-75.
14. Fries JF. Safety, cost and effectiveness issues with disease modifying antirheumatic drugs in rheumatoid arthritis. *Ann Rheum Dis* 1999;58:86-9.
15. Gabriel S, Tugwell P, O'Brien B, et al. Report of the OMERACT task force on economic evaluation. *J Rheumatol* 1999;26:203-6.
16. Kavanaugh AF, Wolfe F, Auslander M, et al. Roundtable II: Cost concerns for rheumatoid arthritis treatment. *Am J Manag Care* 1999;5:S880-S888.
17. Lipsky PE, Kavanaugh A. The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapies. *Rheumatology* 1999;38:41-4.
18. Kantor TG. Order out of chaos — the primary mission of the pyramid [editorial]. *J Rheumatol* 1990;17:1580-1.
19. Smyth CJ. Therapy of rheumatoid arthritis. A pyramidal plan. *Postgrad Med* 1972;51:31-9.
20. Bensen WG, Bensen W, Adachi JD. Back to the future: The pyramids of rheumatoid arthritis. *J Rheumatol* 1997;24:1023-7.
21. Hess EV, Luggen ME. Remodeling the pyramid — a concept whose time has not yet come [editorial]. *J Rheumatol* 1989;16:1175-6.

22. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. *Arthritis Rheum* 1994;37:481-94.
23. Wolfe F, Hawley DJ. Remission in rheumatoid arthritis. *J Rheumatol* 1985;12:245-52.
24. Wolfe F, Pincus T. The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the disease. *J Rheumatol* 2001;28 (in press).
25. Affleck G, Tennen H, Keefe FJ, et al. Everyday life with osteoarthritis or rheumatoid arthritis: independent effects of disease and gender on daily pain, mood, and coping. *Pain* 1999;83:601-9.
26. Kazis LE, Meenan RF, Anderson JJ. Pain in the rheumatic diseases: investigation of a key health status component. *Arthritis Rheum* 1983;26:1017-22.
27. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JMW. Long-term course and outcome of functional capacity in rheumatoid arthritis — The effect of disease activity and radiologic damage over time. *Arthritis Rheum* 1999;42:1854-60.
28. Escalante A, del Rincon I. How much disability in rheumatoid arthritis is explained by rheumatoid arthritis? *Arthritis Rheum* 1999;42:1712-21.
29. Lassere M, Wells G, Tugwell P, Edmonds J. Percentile curve reference charts of physical function: Rheumatoid arthritis population. *J Rheumatol* 1995;22:1241-6.
30. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. *Arthritis Rheum* 1984;27:864-72.
31. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? *Rheum Dis Clin North Am* 1993;19:123-51.
32. Uhlig T, Kvien TK, Glennas A, Smedstad LM, Forre O. The incidence and severity of rheumatoid arthritis. Results from a county register in Oslo, Norway. *J Rheumatol* 1998;25:1078-84.
33. Van der Heide A, Jacobs JW, Haanen HC, Bijlsma JW. Is it possible to predict the first year extent of pain and disability for patients with rheumatoid arthritis? *J Rheumatol* 1995;22:1466-70.
34. Wolfe F, Hawley DJ, Cathey MA. The assessment and prediction of functional disability in RA. *J Rheumatol* 1991;18:1298-306.
35. Wolfe F, Hawley DJ, Cathey MA. Clinical and health status measures over time — prognosis and outcome assessment in rheumatoid arthritis. *J Rheumatol* 1991;18:1290-7.
36. Wolfe F. The natural history of rheumatoid arthritis. *J Rheumatol* 1996;23:13-22.
37. Wolfe F, O'Dell JR, Kavanaugh A, Wilske K, Pincus T. Evaluating severity and status in rheumatoid arthritis. *J Rheumatol* 2001;28:1453-62.
38. Yelin E, Meenan RF, Nevitt M, Epstein WV. Work disability in rheumatoid arthritis: effects of disease, social, and work factors. *Ann Intern Med* 1980;93:551-6.
39. Makisara GL, Makisara P. Prognosis of functional capacity and work capacity in rheumatoid arthritis. *Clin Rheumatol* 1982;1:117-25.
40. Reisine ST, Goodenow C, Grady KE. The impact of rheumatoid arthritis on the homemaker. *Soc Sci Med* 1987;25:89-95.
41. Yelin E, Henke C, Epstein WV. The work dynamics of the person with rheumatoid arthritis. *Arthritis Rheum* 1987;30:507-12.
42. Reisine ST, Grady KE, Goodenow C, Fifield J. Work disability among women with rheumatoid arthritis: The relative importance of disease, social, work, and family factors. *Arthritis Rheum* 1989;32:538-43.
43. Mau W, Bornmann M, Weber H, Weidemann HF, Hecker H, Raspe HH. Prediction of permanent work disability in a follow-up study of early rheumatoid arthritis: Results of a tree structured analysis using RECPAM. *Br J Rheumatol* 1996;35:652-9.
44. Wolfe F, Hawley DJ. The longterm outcomes of rheumatoid arthritis: Work disability: A prospective 18 year study of 823 patients. *J Rheumatol* 1998;25:2108-17.
45. Jantti J, Aho K, Kaarela K, Kautiainen H. Work disability in an inception cohort of patients with seropositive rheumatoid arthritis: a 20 year study. *Rheumatology* 1999;38:1138-41.
46. Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. *J Rheumatol* 1999;26:1681-5.
47. Wolfe F, Zwiilich SH. The long-term outcomes of rheumatoid arthritis: A 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. *Arthritis Rheum* 1998;41:1072-82.
48. Fuchs HA, Pincus T. Radiographic damage in rheumatoid arthritis — description by nonlinear models. *J Rheumatol* 1992;19:1655-8.
49. Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AG, Bacon PA. Progression of radiographical changes in rheumatoid arthritis. *Ann Rheum Dis* 1984;43:8-17.
50. Scott DL, Symmons DPM, Coulton BL, Popert AJ. Long-term outcome of treating rheumatoid arthritis: results after 20 years. *Lancet* 1987;1:1108-11.
51. Sharp JT, Wolfe F, Mitchell DM, Bloch DA. The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first 25 years of disease. *Arthritis Rheum* 1991;34:660-8.
52. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: A 19-year study of radiographic progression. *Arthritis Rheum* 1998;41:1571-82.
53. Felson DT, Anderson JJ, Boers M, et al. American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 1995;38:727-35.
54. Boers M, Tugwell P, Felson DT, et al. World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. *J Rheumatol* 1994;21: Suppl 41:86-9.
55. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. *Arthritis Rheum* 1993;36:729-40.
56. Scott DL, Panayi GS, van Riel PL, et al. Disease activity in rheumatoid arthritis - preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. *Clin Exp Rheumatol* 1992;10:521-5.
57. Smolen JS. The Work of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCSIT). *Br J Rheumatol* 1992;31:219-20.
58. Wolfe F, Lassere M, vanderHeijde D, et al. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. *J Rheumatol* 1999;26:484-9.
59. Wolfe F, Pincus T. Current comment — Listening to the patient — A practical guide to self-report questionnaires in clinical care. *Arthritis Rheum* 1999;42:1797-808.
60. Boers M, van Riel PL, Felson DT, Tugwell P. Assessing the activity of rheumatoid arthritis. *Baillieres Clin Rheumatol* 1995;9:305-17.
61. Houssien DA, Stucki G, Scott DL. A patient-derived disease activity score can substitute for a physician-derived disease activity score in clinical research. *Rheumatology* 1999;38:48-52.
62. Birrell FN, Hassell AB, Jones PW, Dawes PT. Why not use OSRA? A comparison of overall status in rheumatoid arthritis (RA) with ACR core set and other indices of disease activity in RA. *J Rheumatol* 1998;25:1709-15.
63. Wolfe F. The prognosis of rheumatoid arthritis: Assessment of disease activity and disease severity in the clinic. *Am J Med* 1997;103:12-8.
64. Stucki G, Liang MH, Stucki S, Bruhlmann P, Michel BA. A self-

- administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research: Psychometric properties and correlation with parameters of disease activity. *Arthritis Rheum* 1995;38:795-8.
65. Scott DL. A simple index to assess disease activity in rheumatoid arthritis. *J Rheumatol* 1993;20:582-4.
 66. Mason JH, Anderson JJ, Meenan RF, Haralson KM, Lewisstevens D, Kaine JL. The rapid assessment of disease activity in rheumatology (RADAR) questionnaire — validity and sensitivity to change of a patient self-report measure of joint count and clinical status. *Arthritis Rheum* 1992;35:156-62.
 67. van der Heijde DMFM, van't Hof M, van Riel PL, van de Putte LBA. Validity of single variables and indices to measure disease activity in rheumatoid arthritis. *J Rheumatol* 1993;20:538-41.
 68. van der Heijde DMFM, Van't Hof M, van Riel PL, van de Putte LBA. Development of a Disease Activity Score based on judgment in clinical practice by rheumatologists. *J Rheumatol* 1993; 20:579-81.
 69. Hassell AB, Davis MJ, Fowler PD, et al. The relationship between serial measures of disease activity and outcome in rheumatoid arthritis. *Q J Med* 1993;86:601-7.
 70. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis — The impact of poor function and functional decline. *Arthritis Rheum* 1999;42:1209-18.
 71. van Zeben D, Hazes JM, Zwiderman AH, Vandenbroucke JP, Breedveld FC. Factors predicting outcome of rheumatoid arthritis: results of a followup study. *J Rheumatol* 1993;20:1288-96.
 72. Martin JC, Munro R, Campbell MK, Reid DM. Effects of disease and corticosteroids on appendicular bone mass in postmenopausal women with rheumatoid arthritis: comparison with axial measurements. *Br J Rheumatol* 1997;36:43-9.
 73. Alarcón GS. Predictive factors in rheumatoid arthritis. *Am J Med* 1997;103:19-24.
 74. Coste J, Spira A, Clerc D, Paolaggi JB. Prediction of articular destruction in rheumatoid arthritis: Disease activity markers revisited. *J Rheumatol* 1997;24:28-34.
 75. Kuper HH, van Leeuwen MA, van Riel PL, et al. Radiographic damage in large joints in early rheumatoid arthritis: Relationship with radiographic damage in hands and feet, disease activity, and physical disability. *Br J Rheumatol* 1997;36:855-60.
 76. Van der Heide A, Remme CA, Hofman DM, Jacobs JW, Bijlsma JW. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. *Arthritis Rheum* 1995;38:1466-74.
 77. van Leeuwen MA, van Rijswijk MH, van der Heijde DMFM, et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. *Br J Rheumatol* 1993;32 Suppl 3:9-13.
 78. van der Heijde DMFM, van Riel PL, van Leeuwen MA, van't Hof MA, van Rijswijk MH, van de Putte LBA. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. *Br J Rheumatol* 1992;31:519-25.
 79. Nevitt MC, Yelin EH, Henke CJ, Epstein WV. Risk factors for hospitalization and surgery in patients with rheumatoid arthritis: implications for capitated medical payment. *Ann Intern Med* 1986;105:421-8.
 80. Abushakra M, Toker R, Flusser D, et al. Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease-modifying drugs. *Arthritis Rheum* 1998;41:1190-5.
 81. Symmons DPM, Jones MA, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well. *J Rheumatol* 1998;25:1072-7.
 82. Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S. Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. COBRA Trial Group. *Combinatietherapie Bij Reumatoïde Artritis*. *Br J Rheumatol* 1998;37:1102-9.
 83. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. *Arthritis Rheum* 1996;39:616-22.
 84. Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. *Arthritis Rheum* 2000;43:14-21.
 85. Dougados M, Combe B, Cantagrel A, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. *Ann Rheum Dis* 1999;58:220-5.
 86. Rau R, Wassenberg S. Paucity of radiographic progression in rheumatoid arthritis treated with MTX as the first disease modifying antirheumatic drug [letter]. *J Rheumatol* 1999;26:2280.
 87. Alarcón GS, Lopez-Mendez A, Walter J, et al. Radiographic evidence of disease progression in methotrexate treated and non-methotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients — a meta-analysis. *J Rheumatol* 1992;19:1868-73.
 88. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [see comments] [published erratum appears in *Lancet* 1998;351:220]. *Lancet* 1997;350:309-18.
 89. Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis: effects on disease activity in a multicenter prospective study. *J Rheumatol* 1991;18:334-8.
 90. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm prospective study of methotrexate in rheumatoid arthritis: Conclusion after 132 months of therapy. *J Rheumatol* 1998; 25:238-42.
 91. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months. *Arthritis Rheum* 1992;35:138-45.
 92. Kremer JM. Historical overview of the treatment of rheumatoid arthritis with an emphasis on methotrexate. *J Rheumatol* 1996;23:34-7.
 93. Cron RQ, Sharma S, Sherry DD. Current treatment by United States and Canadian pediatric rheumatologists. *J Rheumatol* 1999;26:2036-8.
 94. Hochberg MC. Early aggressive DMARD therapy: The key to slowing disease progression in rheumatoid arthritis. *Scand J Rheumatol* 1999;28:3-7.
 95. Irvine S, Munro R, Porter D. Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice. *Ann Rheum Dis* 1999;58:510-3.
 96. Maravic M, Bologna C, Daures JP, Jorgensen C, Combe B, Sany J. Radiologic progression in early rheumatoid arthritis treated with methotrexate. *J Rheumatol* 1999;26:262-7.
 97. Mottonen TT, Hannonen PJ, Boers M. Combination DMARD therapy including corticosteroids in early rheumatoid arthritis. *Clin Exp Rheumatol* 1999;17:LS59-S65.
 98. Odell JR, Paulsen G, Haire CE, et al. Treatment of early seropositive rheumatoid arthritis with minocycline — Four-year followup of a double-blind, placebo-controlled trial. *Arthritis Rheum* 1999;42:1691-5.
 99. Pincus T. Aggressive treatment of early rheumatoid arthritis to prevent joint damage. *Bull Rheum Dis* 1998;47:2-7.
 100. Rau R, Herborn G, Menninger H, Sangha O. Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate. *Br J Rheumatol* 1998;37:1220-6.

101. Boers M. Combination therapy in rheumatoid arthritis. *Lancet* 1999;354:952.
102. Hawley DJ, Wolfe F, Pincus T. Use of combination therapy in the routine care of patients with rheumatoid arthritis: Physician and patient surveys. *Clin Exp Rheumatol* 1999;17:S78-S82.
103. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. *Lancet* 1999;353:1568-73.
104. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. *N Engl J Med* 1996;334:1287-91.
105. Rau R. Combination DMARD treatment with parenteral gold and methotrexate. *Clin Exp Rheumatol* 1999;17:S83-S90.
106. Weinblatt ME. The role of current strategies in the future treatment of rheumatoid arthritis. *Rheumatology* 1999;38:19-23.
107. Breedveld FC. Future trends in the treatment of rheumatoid arthritis: cytokine targets. *Rheumatology* 1999;38:11-3.
108. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. *Lancet* 1999;354:1932-9.
109. Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. *J Rheumatol* 1999;26:7-15.
110. Wolfe F, Pincus T. Data collection in the clinic. *Rheum Dis Clin North Am* 1995; 21:321-58.
111. Lanes SF, Lanza LL, Radensky PW, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. *Arthritis Rheum* 1997;40:1475-81.
112. Solomon DH, Bates DW, Panush RS, Katz JN. Costs, outcomes, and patient satisfaction by provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the literature and proposed methodologic standards [see comments]. *Ann Intern Med* 1997;127:52-60.
113. Fries JF, Williams CA, Bloch DA. The relative toxicity of nonsteroidal antiinflammatory drugs. *Arthritis Rheum* 1991;34:1353-60.
114. Fries JF, Spitz PW, Mitchell DM, Roth SH, Wolfe F, Bloch DA. Impact of specific therapy upon rheumatoid arthritis. *Arthritis Rheum* 1986;29:620-7.
115. Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models [see comments]. *Am J Med* 1991;91:213-22.
116. Wolfe F, Cathey MA. The effect of age on methotrexate efficacy and toxicity. *J Rheumatol* 1991;18:973-7.
117. Wilkieson CA, Madhok R, Hunter JA, Capell HA. Tolerant, side-effects and efficacy of sulphasalazine in rheumatoid arthritis patients of different ages. *Q J Med* 1993;86:501-5.
118. Albers JM, Kuper HH, van Riel PL, et al. Socio-economic consequences of rheumatoid arthritis in the first years of the disease. *Br J Rheumatol* 1999;38:423-30.
119. Munro R, Hampson R, McEntegart A, Thomson EA, Madhok T, Capell H. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. *Ann Rheum Dis* 1998;57:88-93.
120. Stenger AAME, van Leeuwen MA, Houtman PM, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. *Br J Rheumatol* 1998; 37:1157-63.
121. van de Putte LBA, van Gestel AM, van Riel PLCM. Early treatment of rheumatoid arthritis: rationale, evidence, and implications. *Ann Rheum Dis* 1998;57:511-2.
122. Alarcon GS. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A or methotrexate [comment]. *Arthritis Rheum* 1997;40:791.
123. Van Gestel AM, Haagsma CJ, Furst DE, van Riel PLCM. Treatment of early rheumatoid arthritis patients with slow-acting anti-rheumatic drugs. *Baillieres Clin Rheumatol* 1997;11:65-82.
124. Dawes PT, Fowler PD. Treatment of early rheumatoid arthritis: A review of current and future concepts and therapy. *Clin Exp Rheumatol* 1995;13:381-94.
125. HERA Study Group. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. *Am J Med* 1995;98:156-68.
126. Felson DT, Anderson JJ, Meenan RF. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. *Arthritis Rheum* 1992;35:1117-25.
127. Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. *Arthritis Rheum* 1993;36:297-306.
128. Baker GL, Kahl LE, Zee BC, Stolzer BL, Agarwal AK, Medsger TA Jr. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. *Am J Med* 1987;83:1-9.
129. Csuka M, Carrera GF, McCarty DJ. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine, and hydroxychloroquine. A follow-up study. *JAMA* 1986;255:2315-9.
130. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. *Arch Intern Med* 1999;159:2542-50.
131. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. *Ann Intern Med* 1999;130:478-86.
132. Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. *J Rheumatol* 1999;26 Suppl 57:7-15.
133. Harriman G, Harper LK, Schaible TF. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNF-alpha treatment. *Ann Rheum Dis* 1999;58 Suppl 1:161-4.
134. Pincus T, Callahan LF. The 'side effects' of rheumatoid arthritis: joint destruction, disability and early mortality. *Br J Rheumatol* 1993;32 Suppl 1:28-37.
135. Kirwan JR, Russell AS. Systemic glucocorticoid treatment in rheumatoid arthritis — A debate. *Scand J Rheumatol* 1998; 27:247-51.
136. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. *J Rheumatol* 1997;24:1489-94.
137. Cohen MD, Conn DL. Benefits of low-dose corticosteroids in rheumatoid arthritis. *Bull Rheum Dis* 1997;46:4-7.
138. Saag KG. Low-dose corticosteroid therapy in rheumatoid arthritis: Balancing the evidence. *Am J Med* 1997;103:31-9.
139. Kirwan JR, Byron M, Dieppe P, et al. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. *N Engl J Med* 1995;333:142-6.
140. Criswell LA, Such CL, Yelin EH. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists. *J Rheumatol* 1997;24:2283-90.
141. Gamez-Nava JI, Gonzalez Lopez L, Davis P, Suarez Almazor ME. Referral and diagnosis of common rheumatic diseases by primary care physicians. *Br J Rheumatol* 1998;37:1215-9.
142. Bolunar F, Ruiz MT, Hernandez I, Pascual E. Reliability of the diagnosis of rheumatic conditions at the primary health care level. *J Rheumatol* 1994;21:2344-8.